Literature DB >> 22981162

The Xpert® MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden.

S Y Kim1, H Kim, S Y Kim1, E K Ra, S-I Joo, S Shin, M-W Seong, C-G Yoo, E-C Kim, S S Park.   

Abstract

SETTING: A central hospital laboratory in South Korea.
OBJECTIVE: To evaluate the usefulness of the Xpert® MTB/RIF assay in a country with an intermediate tuberculosis burden.
DESIGN: A total of 71 real-time polymerase chain reaction-positive sputum sediments were tested within 24 h by the Xpert MTB/RIF assay. Mycobacterium tuberculosis detection was compared with smear microscopy and culture. Rifampicin (RMP) resistance was compared with a culture-based method and rpoB gene sequencing. We also assessed the limit of detection for mutant proportions and time savings in diagnosis.
RESULTS: The Xpert MTB/RIF assay detected M. tuberculosis in 71 (100%) specimens (32 smear-positive, 39 smear-negative). This assay showed 100% (62/62) concordance with drug resistance confirmed by culture and 98.4% (61/62) concordance with sequencing. A specimen containing approximately 50% of mutant p.His526Tyr was falsely interpreted as wild-type bacilli by this assay. The minimal detection ratio was 5:1 of mutant vs. wild-type cells. The median time saved was 18.5 days (range 9-30) for the diagnosis of M. tuberculosis and 81.5 days (65-136) for RMP susceptibility in smear-negative, culture-positive patients.
CONCLUSIONS: The Xpert MTB/RIF assay showed high sensitivity in detecting M. tuberculosis with information on RMP resistance, and had a more rapid time to diagnosis compared to conventional tests; however, the location and amount of mutation may affect test sensitivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981162     DOI: 10.5588/ijtld.11.0602

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  7 in total

Review 1.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 2.  Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis.

Authors:  Hanna Nebenzahl-Guimaraes; Karen R Jacobson; Maha R Farhat; Megan B Murray
Journal:  J Antimicrob Chemother       Date:  2013-09-20       Impact factor: 5.790

3.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

4.  Performance evaluation of the Xpert MTB/RIF assay according to its clinical application.

Authors:  Hee Jae Huh; Byeong-Ho Jeong; Kyeongman Jeon; Won-Jung Koh; Chang-Seok Ki; Nam Yong Lee
Journal:  BMC Infect Dis       Date:  2014-11-14       Impact factor: 3.090

5.  Genotypic, Phenotypic and Clinical Validation of GeneXpert in Extra-Pulmonary and Pulmonary Tuberculosis in India.

Authors:  Urvashi B Singh; Pooja Pandey; Girija Mehta; Anuj K Bhatnagar; Anant Mohan; Vinay Goyal; Vineet Ahuja; Ranjani Ramachandran; Kuldeep S Sachdeva; Jyotish C Samantaray
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

6.  Using Xpert MTB/RIF.

Authors:  Mark P Nicol; Andrew Whitelaw; Stevens Wendy
Journal:  Curr Respir Med Rev       Date:  2013-06

Review 7.  Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.

Authors:  Kaican Zong; Chen Luo; Hui Zhou; Yangzhi Jiang; Shiying Li
Journal:  BMC Microbiol       Date:  2019-08-05       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.